{
  "docId": "019de073-4386-7700-b700-92166fcbcd7c",
  "docSlug": "fd316ea801ff13186537922fd8d6b6b2",
  "documentTitle": "BioNTech | Investor Presentation Deck | 28 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 28,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "roadmap",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a Gantt-style visualization to show clinical trial phases for various drug candidates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-4386-7700-b700-92166fcbcd7c/23",
  "deckHref": "/decks/019de073-4386-7700-b700-92166fcbcd7c",
  "deckJsonHref": "/decks/019de073-4386-7700-b700-92166fcbcd7c.json",
  "deckAnchorHref": "/decks/019de073-4386-7700-b700-92166fcbcd7c#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.09,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "SMIM, small molecule immunomodulators. 1 Investigator-initiated Phase 1 trial; 2 Collaboration with Genentech; 3 Collaboration with Sanofi; 4 Collaboration with Genmab.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "133289ed-40fc-4883-9293-719227e4bded",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.92,
        "x": 0.04,
        "y": 0.17
      },
      "kind": "table",
      "text": "Pipeline table with columns: Drug class, Platform, Product candidate, Indication, Pre-clinical, Phase 1, Phase 2, Phase 3, Milestones",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85ea7c2e-5b05-4193-a947-da32b9ff35be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.78,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "Oncology Pipeline: Significant Progress and Expansion in 2022",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc272f8a-41d4-46f7-8880-5a3596f355f5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "3940aa99-3b69-41bd-aa66-528436d59e54",
      "evidence": "The slide contains a table with data on the company's oncology pipeline.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "71e1e013-7cde-4607-8501-43f4a24a053b",
      "evidence": "The pipeline table uses horizontal bars to represent clinical trial phases over time.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 24,
      "from": 19,
      "beatId": "24f1c7cb-ed51-471a-8d42-de7584f2b8af",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "Infectious Diseases and Oncology slides showcase product pipeline",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 28,
      "from": 6,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "3cf6d9b3-9631-47e6-918d-3327cacea976",
      "evidence": "The presentation follows a 'why-what-how' structure",
      "position": 0,
      "objective": "Why BioNTech's approach is necessary and beneficial",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}